Dissociable rate-dependent effects of oral methylphenidate on impulsivity and D2/3 receptor availability in the striatum

Journal of Neuroscience

Volumn 35, Issue 9, 2015, Pages 3747-3755

  Caprioli, Daniele ^a   Jupp, Bianca ^b,c   Hong, Young T ^c   Sawiak, Stephen J ^b,c   Ferrari, Valentina ^c   Wharton, Laura ^b,c   Williamson, David J ^c   McNabb, Carolyn ^d   Berry, David ^e   Aigbirhio, Franklin I ^b,c   Robbins, Trevor W ^b,c   Fryer, Tim D ^b,c   Dalley, Jeffrey W ^b,c  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e EPILEPSY SOCIETY   (United Kingdom)

Author keywords

Addiction; Attention deficit hyperactivity disorder; Dopamine; Methylphenidate; Nucleus accumbens; Positron emission tomography

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; METHYLPHENIDATE; RITALINIC ACID; CENTRAL STIMULANT AGENT; DOPAMINE UPTAKE INHIBITOR;

ADULT; ANIMAL EXPERIMENT; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMPULSIVENESS; MALE; NONHUMAN; PERFORMANCE; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; REACTION TIME; TANDEM MASS SPECTROMETRY; VISUAL STIMULATION; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; METABOLISM; POSITRON EMISSION TOMOGRAPHY;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DOPAMINE UPTAKE INHIBITORS; IMPULSIVE BEHAVIOR; MALE; METHYLPHENIDATE; POSITRON-EMISSION TOMOGRAPHY; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 84924769218     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3890-14.2015     Document Type: Article

References (59)

1. Afonso D, Santana C, Rodriguez M (1993) Neonatal lateralizationof behavior and brain dopaminergic asymmetry. Brain Res Bull 32:11–16.
2. Andrzejewski ME, Spencer RC, Harris RL, Feit EC, McKee BL, Berridge CW (2014) The effects of clinically relevant doses of amphetamine and meth-ylphenidate on signal detection and DRL in rats. Neuropharmacology 79:634–641.
3. Arakawa O (1994) Effects of methamphetamine and methylphenidate on single and paired rat open-field behaviors. Physiol Behav 55:441–446.
4. Arnsten AF (2006) Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry 67 [Suppl 8]:7–12.
5. Avants BB, Epstein CL, Grossman M, Gee JC (2008) Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal 12:26-41.
6. Bari A, Dalley JW, Robbins TW (2008) The applicationofthe 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats. Nat Protoc 3:759–767.
7. Beatty WW, Dodge AM, Dodge LJ, White K, Panksepp J (1982) Psychomo-tor stimulants, social deprivation and play in juvenile rats. Pharmacol Biochem Behav 16:417–422.
8. Belin D, Mar AC, Dalley JW, Robbins TW, Everitt BJ (2008) High impulsiv-ity predicts the switch to compulsive cocaine-taking. Science 320:1352-1355.
9. Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B, Hamilton C, Spencer RC (2006) Methylphenidate preferentially increases catecholamine neurotransmission within the prefron-tal cortex at low doses that enhance cognitive function. Biol Psychiatry 60:1111–1120.
10. Besson M, Belin D, McNamara R, Theobald DE, Castel A, Beckett VL, Crit-tenden BM, Newman AH, Everitt BJ, Robbins TW, Dalley JW (2010) Dissociable control of impulsivity in rats by dopamine d2/3 receptors in the core and shell subregions of the nucleus accumbens. Neuropsychop-harmacology 35:560–569.
11. Biederman J (2005) Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 57:1215–1220.
12. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heili-genstein JH, Morin SM, Gehlert DR, Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperac-tivity disorder. Neuropsychopharmacology 27:699–711.
13. Caprioli D, Hong YT, Sawiak SJ, Ferrari V, Williamson DJ, Jupp B, Adrian Carpenter T, Aigbirhio FI, Everitt BJ, Robbins TW, Fryer TD, Dalley JW (2013) Baseline-dependent effects of cocaine pre-exposure on impulsiv-ity and D2/3 receptor availability in the rat striatum: possible relevance to the attention-deficit hyperactivity syndrome. Neuropsychopharmacol-ogy 38:1460–1471.
14. Caprioli D, Sawiak SJ, Merlo E, Theobald DE, Spoelder M, Jupp B, Voon V, Carpenter TA, Everitt BJ, Robbins TW, Dalley JW (2014) Gamma ami-nobutyric acidergic and neuronal structural markers in the nucleus ac-cumbens core underlie trait-like impulsive behavior. Biol Psychiatry 75: 115–123.
15. Carlson JN, Glick SD (1989) Cerebral lateralization as a source of interindi-vidual differencesinbehavior. Experientia 45:788–798.
16. Clatworthy PL, Lewis SJ, Brichard L, Hong YT, Izquierdo D, Clark L, Cools R, Aigbirhio FI, Baron JC, Fryer TD, Robbins TW (2009) Dopamine release in dissociable striatal subregions predicts the different effects of oral methylphenidate on reversal learning and spatial working memory. J Neurosci 29:4690–4696.
17. Cochran WG, Cox GM (1957) Experimental designs, Ed 2. New York: Wiley.
18. Concha ML, Bianco IH, Wilson SW (2012) Encoding asymmetry within neural circuits. Nat Rev Neurosci 13:832–843.
19. Dalley JW, Fryer TD, Brichard L, Robinson ES, Theobald DE, Lääne K, Peña Y, Murphy ER, Shah Y, Probst K, Abakumova I, Aigbirhio FI, Richards HK, Hong Y, Baron JC, Everitt BJ, Robbins TW (2007) Nucleus accum-bens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 315:1267–1270.
20. Dalley JW, Everitt BJ, Robbins TW (2011) Impulsivity, compulsivity, and top-down cognitive control. Neuron 69:680–694.
21. Defrise M, Kinahan PE, Townsend DW, Michel C, Sibomana M, Newport DF (1997) Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imaging 16:145–158.
22. del Campo N, Fryer TD, Hong YT, Smith R, Brichard L, Acosta-Cabronero J, Chamberlain SR, Tait R, Izquierdo D, Regenthal R, Dowson J, Suckling J, Baron JC, Aigbirhio FI, Robbins TW, Sahakian BJ, Müller U (2013) A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment. Brain 136:3252–3270.
23. DeVito EE, Blackwell AD, Clark L, Kent L, Dezsery AM, Turner DC, Aitken MR, Sahakian BJ (2009) Methylphenidate improves response inhibition but not reflection-impulsivity in children with attention deficit hyperac-tivity disorder (ADHD). Psychopharmacology 202:531–539.
24. Dews PB, Wenger GR (1977) Rate-dependency of the behavioral effects of amphetamine. In: Advances in behavioral pharmacology, Vol 1 (Thompson T, Dews PB, eds), pp 167–227. San Diego, CA: Academic.
25. Economidou D, Pelloux Y, Robbins TW, Dalley JW, Everitt BJ (2009) High impulsivity predicts relapsetococaine-seeking after punishment-induced abstinence. Biol Psychiatry 65:851–856.
26. Economidou D, Theobald DE, Robbins TW, Everitt BJ, Dalley JW (2012) Norepinephrine and dopamine modulate impulsivity on the five-choice serial reaction time task through opponent actions in the shell and core sub-regions of the nucleus accumbens. Neuropsychopharmacology 37: 2057–2066.
27. Gaytan O, Al-Rahim S, Swann A, Dafny N (1997) Sensitization to locomotor effects of methylphenidate in the rat. Life Sciences 61:PL101–PL107.
28. Gill KE, Pierre PJ, Daunais J, Bennett AJ, Martelle S, Gage HD, Swanson JM, Nader MA, Porrino LJ (2012) Chronic treatment with extended release methylphenidate does not alter dopamine systems or increase vulnerability for cocaine self-administration: a study in nonhuman primates. Neu-ropsychopharmacology 37:2555–2565.
29. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, et al. (2007) Consensus nomenclature for in vivo imaging of revers-ibly binding radioligands. J Cereb Blood Flow Metab 27:1533–1539.
30. Jupp B, Caprioli D, Saigal N, Reverte I, Shrestha S, Cumming P, Everitt BJ, Robbins TW, Dalley JW (2013) Dopaminergic and GABA-ergic markers of impulsivity in rats: evidence for anatomical localisation in ventral striatum and prefrontal cortex. Eur J Neurosci 37:1519–1528.
31. Kuczenski R, Segal DS (2002) Exposure of adolescent rats to oral methyl-phenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci 22:7264–7271.
32. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16:834–840.
33. McNamara CG, Davidson ES, Schenk S (1993) A comparison of the motor-activating effects of acute and chronic exposure to amphetamine and methylphenidate. Pharmacol Biochem Behav 45:729–732.
34. Molander AC, Mar A, Norbury A, Steventon S, Moreno M, Caprioli D, Theo-bald DE, Belin D, Everitt BJ, Robbins TW, Dalley JW (2011) High im-pulsivity predicting vulnerability to cocaine addiction in rats: some relationship with novelty preference but not novelty reactivity, anxiety or stress. Psychopharmacology 215:721–731.
35. Moreno M, Economidou D, Mar AC, López-Granero C, Caprioli D, Theobald DE, Fernando A, Newman AH, Robbins TW, Dalley JW (2013) Divergent effects of D(2)/(3) receptor activation in the nucleus accum-bens core and shell on impulsivity and locomotor activity in high and low impulsive rats. Psychopharmacology 228:19–30.
36. Mukherjee J, Yang ZY, Das MK, Brown T (1995) Fluorinated benzamide neu-roleptics–III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol 22:283–296.
37. Patrick KS, Ellington KR, Breese GR (1984) Distribution of methylpheni-date and p-hydroxymethylphenidate in rats. J Pharmacol Exp Ther 231: 61–65.
38. Robb AS, Findling RL, Childress AC, Berry SA, Belden HW, Wigal SB (2014) Efficacy, safety, and tolerability of a novel methylphenidate extended-release oral suspension (MEROS) in ADHD. J Atten Disord. Advance online publication. Retrieved 17 January 2015. doi:10.1177/1087054714533191.
39. Robbins TW (2002) The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology 163:362–380.
40. Robbins TW, Sahakian BJ (1979) “Paradoxical” effects of psychomotor stimulant drugs in hyperactive children from the standpoint of behavioural pharmacology. Neuropharmacology 18:931–950.
41. Rodriguez JS, Morris SM, Hotchkiss CE, Doerge DR, Allen RR, Mattison DR, Paule MG (2010) The effects of chronic methylphenidate administration on operant test battery performance in juvenile rhesus monkeys. Neurotoxicol Teratol 32:142–151.
42. Rodriguez M, Martin L, Santana C (1994) Ontogenic development of brain asymmetry in dopaminergic neurons. Brain Res Bull 33:163–171.
43. Sahakian BJ, Robbins TW (1977) Are the effects of psychomotor stimulant drugs on hyperactive children really paradoxical? Med Hypotheses 3:154–158.
44. Shuster L, Hudson J, Anton M, Righi D (1982) Sensitization of mice to methylphenidate. Psychopharmacology 77:31–36.
45. Soto PL, Wilcox KM, Zhou Y, Kumar A, Ator NA, Riddle MA, Wong DF, Weed MR (2012) Long-term exposure to oral methylphenidate or dl-amphetamine mixture in peri-adolescent rhesus monkeys: effects on physiology, behavior, and dopamine system development. Neuropsycho-pharmacology 37:2566–2579.
46. Swanson JM, Volkow ND (2002) Pharmacokinetic and pharmacodynamic propertiesofstimulants: implications for the designof new treatments for ADHD. Behav Brain Res 130:73–78.
47. Wanson JM, Volkow ND (2009) Psychopharmacology: concepts and opinions about the use of stimulant medications. J Child Psychol Psychiatry 50:180–193.
48. Thanos PK, Michaelides M, Benveniste H, Wang GJ, Volkow ND (2007)Effects of chronic oral methylphenidate on cocaine self-administration and striatal dopamine D2 receptors in rodents. Pharmacol Biochem Be-hav 87:426–433.
49. Tomer R, Goldstein RZ, Wang GJ, Wong C, Volkow ND (2008) Incentive motivation is associated with striatal dopamine asymmetry. Biol Psychol 77:98–101.
50. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ (2003) Relative lack of cognitive effects of methylphenidate in elderly male volunteers. Psychopharmacology 168:455–464.
51. van der Schaaf ME, Fallon SJ, Ter Huurne N, Buitelaar J, Cools R (2013) Working memory capacity predicts effects of methylphenidate on reversal learning. Neuropsychopharmacology 38:2011–2018.
52. Vanderschuren LJ, Trezza V, Griffioen-Roose S, Schiepers OJ, Van Leeuwen N, De Vries TJ, Schoffelmeer AN (2008) Methylphenidate disrupts social play behavior in adolescent rats. Neuropsychopharmacology 33: 2946–2956.
53. Volkow ND, Insel TR (2003) What are the long-term effects of methyl-phenidate treatment? Biol Psychiatry 54:1307–1309.
54. Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, Fowler JS, Logan J, Ma Y, Schulz K, Pradhan K, Wong C, Swanson JM (2007a) Depressed dopamine activity in caudate and preliminary evidence of limbic involve-ment in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 64:932–940.
55. Volkow ND, Wang GJ, Newcorn J, Fowler JS, Telang F, Solanto MV, Logan J, Wong C, Ma Y, Swanson JM, Schulz K, Pradhan K (2007b) Brain dopa-mine transporter levels in treatment and drug naive adults with ADHD. Neuroimage 34:1182–1190.
56. Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, Fowler JS, Zhu W, Logan J, Ma Y, Pradhan K, Wong C, Swanson JM (2009) Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA 302:1084–1091.
57. Volkow ND, Wang GJ, Tomasi D, Kollins SH, Wigal TL, Newcorn JH, Telang FW, Fowler JS, Logan J, Wong CT, Swanson JM (2012) Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. J Neurosci 32:841-849.
58. Wilens TE (2008) Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 28:S46–S53.
59. Zetterström T, Sharp T, Collin AK, Ungerstedt U (1988) In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC. Eur J Pharmacol 148:327–334.